BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//6.6.4.4//EN
TZID:Asia/Jerusalem
X-WR-TIMEZONE:Asia/Jerusalem
BEGIN:VEVENT
UID:962@biotech.technion.ac.il
DTSTART;TZID=Asia/Jerusalem:20200923T170000
DTEND;TZID=Asia/Jerusalem:20220202T164952
DTSTAMP:20220512T124720Z
URL:https://biotech.technion.ac.il/events/developing-a-pancreatic-ecm-base
 d-3d-microencapsulation-platform-for-diabetes-therapy-2/
SUMMARY:Developing a Pancreatic ECM-based 3D Microencapsulation Platform fo
 r Diabetes Therapy
DESCRIPTION:Encapsulation of insulin–producing cells (IPCs) has been wide
 ly investigated to improve cell transplantation outcomes in diabetic patie
 nts. Nonetheless\, major hurdles impede the technology from reaching the c
 linic\, some of which being the limited survival of isolated beta cells an
 d the inability of polymers used in the encapsulation process to mimic the
  natural pancreatic niche. To surmount these obstacles\, we present a uniq
 ue microencapsulation platform incorporating a natural bioactive material:
  porcine pancreatic extracellular matrix (pECM). In this research\, pECM-b
 ased encapsulation platforms were designed for each of two cell types - pa
 ncreatic islets\, the gold standard of diabetes-cell-based therapy\, and h
 uman induced pluripotent stem cells (hiPSCs)\, a possible source for IPC d
 erivation. Encapsulated hiPSCs proliferated within the pECM microcapsules 
 in culture\, forming spherical aggregates. Eight weeks following implantat
 ion within healthy mice\, encapsulated hiPSCs sustained their viability wi
 th no evidence of cell leakage from the capsules into the surrounding tiss
 ue. pECM-encapsulation supported murine islet viability and significantly 
 improved their insulin secretion over time\, compared to alginate-encapsul
 ation. Implantation in healthy mice did not elicit an inflammatory respons
 e\, and islets remained viable and functional. Moreover\, normoglycemia wa
 s achieved within 2 days in 100% of immunocompetent diabetic mice implante
 d with islets encapsulated in pECM microcapsules\, as opposed to only 50% 
 receiving alginate-encapsulated islets. Wednesday\, 23/09/\n\n \n\nAbstra
 ct
END:VEVENT
BEGIN:VTIMEZONE
TZID:Asia/Jerusalem
X-LIC-LOCATION:Asia/Jerusalem
BEGIN:DAYLIGHT
DTSTART:20200327T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20201025T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20210326T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20211031T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
END:VTIMEZONE
END:VCALENDAR